278.44
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$275.21
Aprire:
$272.07
Volume 24 ore:
376.92K
Relative Volume:
1.65
Capitalizzazione di mercato:
$7.52B
Reddito:
$2.58B
Utile/perdita netta:
$-778.69M
Rapporto P/E:
-10.19
EPS:
-27.33
Flusso di cassa netto:
$223.75M
1 W Prestazione:
+2.63%
1M Prestazione:
-6.47%
6M Prestazione:
-4.92%
1 anno Prestazione:
+4.82%
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Nome
Bio Rad Laboratories Inc
Settore
Industria
Telefono
(510) 724-7000
Indirizzo
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
BIO
Bio Rad Laboratories Inc
|
278.44 | 7.43B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
116.35 | 202.16B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
387.46 | 147.74B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
97.66 | 124.39B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
76.85 | 112.40B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
86.47 | 49.85B | 6.07B | 1.06B | 799.60M | 1.8527 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-08-28 | Iniziato | Wells Fargo | Equal Weight |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-04-03 | Downgrade | Citigroup | Buy → Neutral |
| 2023-12-07 | Iniziato | UBS | Buy |
| 2023-06-16 | Iniziato | Wells Fargo | Overweight |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-01-28 | Reiterato | Citigroup | Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2018-10-17 | Iniziato | Goldman | Buy |
| 2018-09-20 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Downgrade | CL King | Buy → Neutral |
| 2017-07-13 | Iniziato | Wells Fargo | Outperform |
| 2017-06-28 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Iniziato | Deutsche Bank | Hold |
| 2016-10-13 | Iniziato | CL King | Buy |
| 2015-05-06 | Reiterato | Jefferies | Buy |
| 2009-12-18 | Iniziato | Maxim Group | Buy |
| 2009-11-06 | Iniziato | Jefferies & Co | Buy |
| 2009-07-17 | Iniziato | Soleil | Buy |
| 2007-09-26 | Iniziato | Banc of America Sec | Buy |
| 2007-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
Mostra tutto
Bio Rad Laboratories Inc Borsa (BIO) Ultime notizie
Westfield Capital Management Co. LP Increases Stock Holdings in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Bio-Rad Laboratories, Inc. $BIO Shares Sold by Vanguard Group Inc. - MarketBeat
A Look At Bio Rad Laboratories (BIO) Valuation After Recent Share Price Weakness - simplywall.st
(BIO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Molecular Biology Analyzers Market Set to Boom by 2033: - openPR.com
Microfluidics Research Report 2026-2035: A $20.73 Billion - GlobeNewswire
Microfluidics Research Report 2026-2035: A $20.73 Billion Market by 2030 with Thermo Fisher Scientific, PerkinElmer, Dolomite, Agilent Technologies, Bio-Rad Laboratories, and Fluidigm Leading - Yahoo Finance
Bio-Rad Laboratories (NYSE:BIO.B) Shares Pass Below 200-Day Moving AverageTime to Sell? - MarketBeat
Weekly Earnings: What is the long term forecast for Bio Rad Laboratories Inc stockJuly 2025 Reactions & High Win Rate Trade Alerts - baoquankhu1.vn
International Markets and Bio-Rad (BIO): A Deep Dive for Investors - Yahoo Finance
Bio-Rad Laboratories, Inc. $BIO Shares Sold by ICICI Prudential Asset Management Co Ltd - MarketBeat
Blood Grouping Reagents Market Top Key Players -Grifols, Roche, - openPR.com
Hemocytometer Market Is Going to Boom Rapidly With Top Key - openPR.com
CenterBook Partners LP Has $2.56 Million Holdings in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
4 Undervalued Life Sciences Tools & Services Stocks for Thursday, February 19 - AAII
Bio-Rad Updates Investors on Sartorius Strategic Investment Metrics - TipRanks
Bio-Rad Laboratories, Inc. (BIO) achieves modest revenue growth and robust free cash flow growth - MSN
Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth - Finviz
Risk Hedge: Is RBOT still a buy after recent gains2025 Institutional Moves & Stock Timing and Entry Methods - baoquankhu1.vn
Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down - Yahoo Finance
Protein Engineering Market to Grow at 15.6% CAGR from 2025 - openPR.com
Bio-Rad Laboratories, Inc. (NYSE:BIO) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Protein Engineering Market Is Going to Boom Rapidly With Top Key - openPR.com
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
United States Molecular Quality Controls Market to Reach CAGR - openPR.com
Dematic Automation Solution drives precision and productivity for Bio-Rad Singapore - mhdsupplychain.com.au
MSN Money - MSN
Is It Time To Reassess Bio-Rad Laboratories (BIO) After Multi Year Share Price Weakness - Yahoo Finance
Assessing Bio-Rad Laboratories (BIO) Valuation After Prolonged Share Price Weakness - Yahoo Finance
Bio-Rad Laboratories (BIO) Returns To Profitability With Diagnostics Rebound – Is The Turnaround Durable? - Yahoo Finance
Bio-Rad Laboratories Q4 2025 sales up 9% to USD 693.2M - Medical Buyer
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2025 earnings call transcript - MSN
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2025 Earnings Call Transcript - Insider Monkey
Bio-Rad Laboratories (NYSE:BIO) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Beyond the Balance Sheet: What SWOT Reveals About Bio-Rad Labora - GuruFocus
Will Bio Rad Laboratories Inc. benefit from geopolitical trendsWeekly Profit Report & Low Risk Entry Point Tips - mfd.ru
Bio-Rad Q4 2025 slides reveal modest growth amid segment divergence and strategic shifts - Investing.com Nigeria
Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap DownHere's What Happened - MarketBeat
Bio-Rad Laboratories Inc (BIO) Shares Down 11.17% on Feb 13 - GuruFocus
Oversold Conditions For Bio-Rad Laboratories (BIO) - Nasdaq
UBS Adjusts Price Target on Bio-Rad Laboratories to $335 From $350, Maintains Buy Rating - marketscreener.com
Bio-Rad Laboratories (BIO) Shares Cross Below 200 DMA - Nasdaq
Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down After Earnings Miss - MarketBeat
Bio-Rad Laboratories, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Pinterest Posts Downbeat Results, Joins DraftKings, Toast, Expedia And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
S&P 500 Futures Drop In Premarket Trading; Pinterest, Bio-Rad Labs A Lag - 富途牛牛
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
BIO-RAD LABORATORIES, INC. SEC 10-K Report - TradingView
Bio-Rad (BIO) Reports Q4 Revenue Growth and Strategic Initiatives - GuruFocus
Bio-Rad Laboratories, Inc. $BIO Holdings Lifted by Envestnet Asset Management Inc. - MarketBeat
Bio Rad Laboratories Inc Azioni (BIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):